IHS Chemical Week

Chemical Week Magazine :: Pharmaceuticals & Fine Chemicals

DSM Biologics to Produce Antibody for MorphoSys

10:48 AM MDT | August 25, 2008 | Deepti Ramesh

DSM Biologics, a unit of DSM, says it has signed a biopharmaceutical manufacturing agreement with biotech firm MorphoSys (Martinsried, Germany). The deal calls for DSM to develop and manufacture MOR202, a fully human antibody for the treatment of multiple myeloma, at its facility in Groningen, Netherlands. Financial terms were not disclosed. Sproll: Continuing the PER.C6 platform. DSM will use the PER.C6 technology platform of biotech firm Crucell (Leiden, Netherlands). PER.C6 has been developed for large-scale manufacturing of biopharma products including...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa